EGFR and head and neck squamous cell carcinoma: Based on improved survival data, Cetuximab, an EGFR inhibitor, was approved for locally, regionally advanced, recurrent, and metastatic HNSCC, while development of novel EGFR-targeting therapies and combination regimens is under active investigation [80,81].